Table 2 Distribution of the population according to the antipsychotic used (the table only shows those drugs that were used in more than 1% of the total sample)
From: Antipsychotic polypharmacy in a regional health service: a population-based study
Drug | Initial sample (N = 71,004) | People given monotherapy (N = 47,386) | People given antipsychotics in combination (N = 9,855) | |
|---|---|---|---|---|
People N(%) | packages N(%) | N(%) | N(%)(*) | |
Risperidone (oral) | 21,537 (30.3) | 137,234 (13.8) | 11,589 (24.5) | 3,586 (36.4) |
Olanzapine | 17,895 (25.2) | 174,715 (17.6) | 9,619 (20.3) | 3,657 (37.1) |
Quetiapine | 13,292 (18.7) | 154,408 (15.5) | 5,913 (12.5) | 2,883 (29.3) |
Haloperidol | 11,053 (15.6) | 91,328 (9.2) | 4,431 (9.4) | 2,750 (27.9) |
Sulpiride | 8,274 (11.7) | 75,183 (7.6) | 6,933 (14.6) | 360 (3.7) |
Levomepromazine | 7,503 (10.6) | 86,794 (8.7) | 2,435 (5.1) | 2,607 (26.5) |
Clothiapine | 4,416 (6.2) | 33,490 (3.4) | 628 (1.3) | 2,157 (21.9) |
Risperidone (LAI) | 3,146 (4.4) | 60,524 (6.1) | 654 (1.4) | 1,500 (15.2) |
Amisulpride | 2,910 (4.1) | 24,957 (2.5) | 655 (1.4) | 1,253 (12.7) |
Aripiprazole | 2,855 (4.0) | 23,551 (2.4) | 664 (1.4) | 1,025 (10.4) |
Ziprasidone | 2,560 (3.6) | 19,757 (2.0) | 721 (1.5) | 875 (8.9) |
Perphenazine | 2,146 (3.0) | 15,616 (1.6) | 797 (1.7) | 623 (6.3) |
Clozapine | 1,615 (2.3) | 35,222 (3.5) | 667 (1.4) | 652 (6.6) |
Fluphenazine | 1,403 (2.0) | 6,113 (0.6) | 212 (0.4) | 531 (5.4) |
Chlorpromazine | 1,209 (1.7) | 9,577 (1.0) | 369 (0.8) | 387 (3.9) |
Zuclopenthixol (LAI) | 1,175 (1.7) | 15,406 (1.5) | 202 (0.4) | 659 (6.7) |
Trifluoperazine | 1,163 (1.6) | 11,912 (1.2) | 280 (0.6) | 367 (3.7) |